Longeveron Inc. (LGVN)
| Market Cap | 24.20M +7.9% |
| Revenue (ttm) | 1.22M -45.3% |
| Net Income | -22.43M |
| EPS | -1.12 |
| Shares Out | 31.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 520,820 |
| Open | 0.7700 |
| Previous Close | 0.7660 |
| Day's Range | 0.7205 - 0.7978 |
| 52-Week Range | 0.4750 - 1.2300 |
| Beta | -0.25 |
| Analysts | Buy |
| Price Target | 7.15 (+871.07%) |
| Earnings Date | Aug 12, 2026 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated... [Read more]
Financial Performance
In 2025, Longeveron's revenue was $1.20 million, a decrease of -49.87% compared to the previous year's $2.39 million. Losses were -$22.70 million, -7.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for LGVN stock is "Buy." The 12-month stock price target is $7.15, which is an increase of 871.07% from the latest price.
News
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chron...
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relate...
Longeveron presents positive laromestrocel data in Alzheimer’s disease
Longeveron (LGVN) announced the presentation of additional data from its Phase 2a CLEAR-MIND clinical trial of laromestrocel in patients with mild Alzheimer’s disease. The findings, presented at the A...
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer's Disease Gray And White Matter Regions A...
Longeveron appoints Marie Washburn CFO
Longeveron (LGVN) announced that the company has appointed Marie Washburn to the company’s executive leadership team in the role of senior VP and CFO, principal financial officer and principal account...
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating it...
Longeveron Transcript: AGM 2026
The meeting covered director elections, share authorization increases, a reverse stock split, incentive plan amendments, and auditor ratification. All proposals passed by majority vote, and voting results will be reported on Form 8-K. Questions from stockholders will be answered online.
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)
MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat...
Longeveron granted SME status by European Medicines Agency
Longeveron (LGVN) announced that the company has been granted small or medium-sized enterprise, or SME, status by the European Medicines Agency, or EMA, which offers benefits leading up to and…
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat...
Longeveron to Present at BIO International Convention 2026
Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportunities for its 4 stem cell therapy developmet programs.
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relate...
Longeveron Proxy statement: Proxy filing
Longeveron filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Longeveron Proxy statement: Proxy filing
Longeveron filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Longeveron reports Q1 EPS (19c) vs. (34c) last year
Reports Q1 revenue $398,000, consensus $323,000. “Earlier this year, we initiated a strategic repositioning of Longeveron (LGVN) designed to maximize shareholder value while maintaining disciplined ca...
Longeveron Earnings Call Transcript: Q1 2026
Q1 2026 saw stable revenue, reduced expenses, and a narrowed net loss, with cash runway into Q4 2026. Key focus is on the ELPIS II HLHS trial, with top-line data expected in August and immediate FDA engagement planned. Strategic repositioning and new investments support long-term growth.
Longeveron Quarterly report: Q1 2026
Longeveron has published its Q1 2026 quarterly earnings report on May 13, 2026.
Longeveron Earnings release: Q1 2026
Longeveron released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric diseas...
Longeveron Slides: Investor presentation
Longeveron has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Longeveron reports DMC approval for laromestrocel study to continue as designed
Longeveron (LGVN) announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial evaluating...
Longeveron downgraded to Hold from Buy at Maxim
Maxim downgraded Longeveron (LGVN) to Hold from Buy.
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment...
Longeveron provides update on laromestrocel development after Type C meeting
Longeveron (LGVN) announced that a constructive Type C meeting with the FDA was held in late March, with the FDA providing their meeting summary in late April, to discuss the…
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agin...